|
|
|
|
|
|
|
|
|
|
|
| Experimental Information | |
| Enzymatic Activity | |
| Molecule Id | EGIN0003528 |
| PMID | 7990108 |
| Assay Used | Kinase assay and HaCaT keratinocyte proliferation assay |
| Experimently Validated | Yes |
| EGFR (IC50) | > 100000 nM |
| HER2 (IC50) | - |
| HER4 (IC50) | - |
| Mutant L858R (IC50) | - |
| Mutant T790M (IC50) | - |
| Double Mutant (IC50) | - |
| Average ERBB2 and ERBB1 (IC50) | - |
| Inhibition EGFR (%) | - |
| Inhibitory Concentration | - |
| Inhibition HER2 (%) | - |
| Inhibitory Concentration | - |
| Ki (EGFR) | - |
| Ki (HER2) | - |
| Ki (HER4) | - |
| Kd (EGFR) | - |
| Kd (L858R) | - |
| Kd (T790M) | - |
| Kd (L858R/T790M) | - |
| Kd (Other mutation) | - |
| Note | The paper describes the novel antiproliferative agents aerived from Lavendustin A |
| Extra | - |
| Cellular Activity | ||||||||||||||
| S.No. | Cell Line | Desp. | IC50 | IC80 | ED50 | GI50 | GI90 | EC50 | Kd | Inhibition (%) | Inhibitory Conc. | |||
| 1 | A431 | - | 213000 ±28000 nM | - | - | - | - | - | - | - | - | |||
| 2 | B16F1 | - | 269000 nM | - | - | - | - | - | - | - | - | |||
| 3 | HaCaT | - | 40 nM | - | - | - | - | - | - | - | - | |||
| 4 | HeLa | - | 470000 ±212100 nM | - | - | - | - | - | - | - | - | |||
| 5 | K562 | - | 217500 ±31800 nM | - | - | - | - | - | - | - | - | |||
| 6 | KB | - | 191500 ±12000 nM | - | - | - | - | - | - | - | - | |||
| 7 | L1210 | - | 415000 ± 7100 nM | - | - | - | - | - | - | - | - | |||
| 8 | LOVO | - | 185000 ±7100 nM | - | - | - | - | - | - | - | - | |||
| 9 | MCF-7 | - | 19000 ± 8500 nM | - | - | - | - | - | - | - | - | |||
| 10 | MDA-MB-231 | - | 427500 ±130800 nM | - | - | - | - | - | - | - | - | |||
| 11 | MDA-MB-468 | - | 46500 ±14100 nM | - | - | - | - | - | - | - | - | |||
| 12 | P388 | - | 337500 ± 123700 nM | - | - | - | - | - | - | - | - | |||
| 13 | SCL-1 | - | 383000 nM | - | - | - | - | - | - | - | - | |||
| 14 | SKBR3 | - | 31000 ±1400 nM | - | - | - | - | - | - | - | - | |||
| 15 | u937 | - | 320000 nM | - | - | - | - | - | - | - | - | |||
| Activity against Receptor | |
| EGFR | Yes |
| HER2 | - |
| HER4 | - |
| Wild type | Yes |
| Mutant | - |
| Inhibitor Binding | |
| EGFR | - |
| HER2 | - |
| HER4 | - |